Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

754 - Baseline prevalence of cardiovascular disease (CVD) risk factors in women with breast cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Breast Cancer

Presenters

Nirmala Bhoo-Pathy

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

N. Bhoo-Pathy1, S. Subramaniam2, H. Zaharah3, Y.C. Kong4, N.A. Taib5, A. Deniel6, K. Chee7, R.S. Bustamam6, M. See5, A. Fong8, C.H. Yip9

Author affiliations

  • 1 Centre For Clinical Epidemiology And Evidence Based Medicine, Faculty of Medicine, University of Malaya, 59100 - Kuala Lumpur/MY
  • 2 Clinical Epidemiology Unit, National Clinical research Centre, Ministry of Health Malaysia, 50586 - Kuala Lumpur/MY
  • 3 Radiotherapy And Oncology, National Cancer Institute, 62250 - Putrajaya/MY
  • 4 Clinical Epidemiology Unit, National Clinical research Centre, 50586 - Kuala Lumpur/MY
  • 5 Dept Of Surgery, University Malaya Medical Center, 59100 - Kuala Lumpur/MY
  • 6 Radiotherapy And Oncology, Kuala Lumpur Hospital, Kuala Lumpur/MY
  • 7 Cardiology Unit, University Malaya Medical Center, 59100 - Kuala Lumpur/MY
  • 8 Heart Centre, Sarawak General Hospital, Kuching/MY
  • 9 Breast Clinic, Subang Jaya Medical Centre, Subang Jaya/MY
More

Resources

Abstract 754

Background

Pre-existing CVD risk factors in women with breast cancer increases their risk of developing adjuvant therapy induced cardiotoxicity. We measured the prevalence of major CVD risk factors in women newly diagnosed with breast cancer in a multiethnic setting.

Methods

From 2015 to 2017, 2159 women with newly diagnosed invasive breast cancer were consecutively recruited from four tertiary hospitals in Malaysia. Demographic, medical and drug history were collected through interviews and verified with medical records. Pre-treatment height, weight, blood pressure, serum glucose, and cholesterol levels were measured. Risk of cardiotoxicity was estimated using the Cardiotoxicity Risk Score proposed by Herrmann, et al.

Results

Median age at diagnosis was 54 years. Median tumor size at presentation was 2.7 cm and 54% had node-negative disease. A majority (70%) of patients had estrogen receptor positive tumors. Prevalence of hypertension was 43%, while hypercholesterolemia was found in 48%. Seventeen percent of patients had diabetes mellitus and 19% were obese. Only 2% were current smokers. Four percent of patients had pre-existing coronary heart disease, arrhythmias or valvular disease. Overall, 40% of patients presented with two or more major CVD risk factors (clustering). The clustering of CVD risk factors was substantial across all age groups; age < 40 years: 16%, 40-49 years: 24%, 50-64 years: 46%, > =65 years: 62%. The Malay and Indian patients were twice more likely to have CVD risk clustering than the Chinese. Of 1880 patients with non-metastatic breast cancer, 45% were planned for anthracycline-based chemotherapy, and 54% for adjuvant radiotherapy. Taking the adjuvant treatment plan into account, it appeared that approximately one in two women with breast cancer in our settings were at high risk of developing cardiotoxicity.

Conclusions

Our findings highlight the need to accelerate the establishment of coordinated partnerships between the oncology and cardiology specialties to improve cardiac outcomes following breast cancer. In the era of precision medicine, these findings also lend support to the notion that the next generation adjuvant therapy decision-making tools in breast cancer should incorporate data on major CVD risk factors.

Clinical trial identification

Legal entity responsible for the study

Nirmala Bhoo-Pathy.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.